Skip to content
Peptigraph home

Bimagrumab Phase 2 trial (NCT05616013)

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
507
actual
Start
16 Nov 2022 (actual)
Primary completion
16 May 2024 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05616013 study arms
ArmTypeInterventionsDescription
Placebo/30 mg/kg BimagrumabPlacebo comparatorOther: PlaceboParticipants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64.
10/30 mg/kg BimagrumabExperimentalBiological: BimagrumabParticipants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64.
30 mg/kg BimagrumabExperimentalBiological: BimagrumabParticipants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64.
Placebo + 1.0 mg SemaglutideExperimentalDrug: Semaglutide; Other: PlaceboParticipants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg
Placebo + 2.4 mg SemaglutideExperimentalDrug: Semaglutide; Other: PlaceboParticipants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg
10 mg/kg Bimagrumab + 1.0 mg SemaglutideExperimentalBiological: Bimagrumab; Drug: SemaglutideParticipants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg
10 mg/kg Bimagrumab + 2.4 mg SemaglutideExperimentalBiological: Bimagrumab; Drug: SemaglutideParticipants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg
30 mg/kg Bimagrumab + 1.0 mg SemaglutideExperimentalBiological: Bimagrumab; Drug: SemaglutideParticipants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg
30 mg/kg Bimagrumab + 2.4 mg SemaglutideExperimentalBiological: Bimagrumab; Drug: SemaglutideParticipants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg
Endpoints

Primary endpoint

NCT05616013 primary outcomes
MeasureTime frame
Change From Baseline in Body Weight at Week 48Baseline, Week 48
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05616013 secondary outcomes
MeasureTime frame
Change From Baseline in Waist Circumference at Week 48Baseline, Week 48
Change From Baseline in Waist Circumference at Week 72Baseline, Week 72
Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48Baseline, Week 48
Change From Baseline in Total Body Fat Mass in kg at Week 72Baseline, Week 72
Percent Change From Baseline for Fat Mass by DXA at Week 48Baseline, Week 48
Percent Change From Baseline for Fat Mass by DXA at Week 72Baseline, Week 72
Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48Baseline, Week 48
Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72Baseline, Week 72
Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48Week 48
Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48Week 48
Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48Week 48
Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48Week 48
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05616013.

Week 48 body weight results posted for the bimagrumab and semaglutide study

The posted primary outcome is the change from baseline in body weight at week 48.[1]

Outcome group OG008 is labelled 30 mg/kg Bimagrumab + 2.4 mg Semaglutide.[1]

Outcome group OG004 is labelled Placebo + 2.4 mg Semaglutide.[1]

The posted least-squares mean change for outcome group OG004 (placebo plus semaglutide) was -14.24 kg, with a spread of 1.17.[1]

The posted change for outcome group OG008 (the highest bimagrumab level combined with semaglutide) was -17.79 kg, with a spread of 1.29.[1]

Sources

  1. 1A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and WomenClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.